36 results about "Macrophage colony-stimulating factor" patented technology

The present invention discloses an enhanced tumor vaccine adjuvant, and specifically relates to the field of vaccine adjuvants, the adjuvant comprising granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-9 (IL-9), gamma interferon (IFN-γ) and at least one additional immunomodulatory factor, wherein the immunomodulatory factor is selected from tumor-specific antigen WT1, CD40 ligand (CD40L), Toll-like receptor agonist or a combination thereof. The tumor vaccine adjuvant of the present invention can enhance the body's immune response to the tumor vaccine and improve the prevention and treatment effect of the tumor vaccine on tumors.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

The present disclosure relates to methods of treating a subject suffering from an eosinophil-associated chronic obstructive pulmonary disease (COPD) or asthma-COPD overlap (ACO) using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The present disclosure relates to the treatment of cancer with granulocyte-macrophage colony-stimulating factor and checkpoint inhibitor agents.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

This invention relates to the field of cell biology, specifically to a co-culture cell model and method for primary glial cells and neurons. The method for co-culturing primary glial cells and neurons provided by this invention includes the following steps: a mixture of primary glial cells and neurons is seeded into a first co-culture medium for pre-culture; the medium is discarded and the cells are washed; a second co-culture medium is added for a first-stage culture; after the first-stage culture, a second-stage culture is performed; the medium used in the second-stage culture is a third co-culture medium supplemented with macrophage colony-stimulating factor; after the second-stage culture, a third-stage culture is performed; the medium used in the third-stage culture is the second co-culture medium; in the obtained co-culture cell model, microglia are differentiated and mature, and are in a quiescent state, thus obtaining a primary glial cell and neuron co-culture model.

The invention relates to a construction method of a peripheral red blood cell humanized mouse, which comprises the following steps: transplanting human hematopoietic stem cells into the mouse and then applying a red blood cell inducer to the mouse, or applying a red blood cell inducer to the mouse and then infusing human red blood cells into the mouse. The red blood cell inducer comprises an antibody targeting mouse macrophage, dexamethasone or a derivative thereof, and a human macrophage colony stimulating factor. In a mouse transplanted with human hematopoietic stem cells, one or more of an antibody targeting mouse macrophages, dexamethasone and a human macrophage colony stimulating factor can be used in the red blood cell induced maturation process, and high-level human red blood cell reconstruction can be quickly realized within three weeks; the maturity and the denucleation ratio of peripheral human erythrocytes reconstructed in the mouse are completely consistent with those of normal human blood; in a mouse transplanted with human erythrocytes, the erythrocyte induction process can be single treatment of an antibody or dexamethasone, or combined use of the antibody and dexamethasone. The invention also provides application of the peripheral erythrocyte humanized mouse.

A method of differentiating pluripotent stem cells into hemangioblasts comprising incubating the pluripotent stem cells in a first serum-free differentiation medium comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to induce differentiation of the pluripotent stem cells into hemangioblasts or hemangioblast-containing embryoid bodies is provided. The hemangioblasts or embryoid bodies may be cultured in a second differentiation medium comprising at least granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin-3 (IL-3) for a period of time sufficient to generate alveolar-like macrophages.

The invention discloses a method for testing neoantigen immunogenicity, which can effectively screen neoantigens with higher immunogenicity through bioinformatics analysis and in-vitro function verification. The method comprises the following steps: firstly, screening an antigen which is remarkably different from a self-proteome through sequence alignment, so as to improve the specificity and effectiveness of immunotherapy, and secondly, culturing a mononuclear cell in a culture medium containing a granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin 4 (IL-4), so as to rapidly induce the mononuclear cell to differentiate into an immature dendritic cell. And under the action of subsequent TNF-alpha, IL-1beta, IL-6 and PGE2, the dendritic cells are further mature, so that the dendritic cells have efficient antigen presentation capability.

The present application relates to the technical field of immune detection, and particularly relates to a granulocyte-macrophage colony stimulating factor determination kit and a detection method thereof. The granulocyte-macrophage colony stimulating factor determination kit comprises GM-CSF magnetic microparticles, GM-CSF luminescent markers, an analysis buffer, a calibrant 1, a calibrant 2, a quality control 1 and a quality control 2. The GM-CSF magnetic microparticles, a sample or the calibrant or the quality control and the analysis buffer are sequentially added, and after incubation and cleaning, the GM-CSF luminescent markers are added for incubation and cleaning, and then the substrate A liquid and the substrate B liquid are sequentially added, and the luminescence intensity is immediately measured, the GM-CSF concentration is calculated according to a calibration curve, the total detection time can be controlled to be about 1 hour, the detection efficiency is greatly improved, and the method can better meet the needs of clinical emergency and high-speed screening. The detection method is simple in operation, fast and accurate in result, and easy to realize automatic high-throughput detection.

The present invention discloses a SINV infectious vector and its application in the preparation of anti-tumor drugs, wherein the SINV infectious vector uses pSINV as a backbone vector, and granulocyte-macrophage colony stimulating factor GM-CSF is connected to the backbone vector. The SINV infectious vector of the present invention can more stably express the inserted exogenous gene, and the biological characteristics of the virus are not significantly different from those of the wild type; the SINV virus particles of the present invention can replicate in cervical cancer Hela tumor cells and liver cancer Hep3B tumor cells, selectively infect tumor cells, and achieve a killing effect on tumors in an immunodeficient mouse model, which has important practical significance and wide application value for applied research and basic research such as oncolytic treatment of cervical cancer and liver cancer.

The invention discloses a culture medium for rapid production of DC cells and application of the culture medium, and belongs to the technical field of immune cell production. The culture medium for rapid production of DC cells contains interleukin-4 (IL-4), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-15 (IL-15) and stem cell factor (SCF), is used for rapid production of DC cells, and can be used for rapid production of DC cells through culture for about 65 hours by taking mononuclear cells from peripheral blood as starting materials. According to the method, the high-purity and high-functionality DC cells are rapidly and efficiently generated, the induction time is short, and the cell purity and functionality are remarkably improved.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

Provided are an oncolytic virus preparation capable of crossing a blood-brain barrier, a preparation method therefor and a use thereof. The oncolytic virus preparation is an oncolytic virus modified by a polypeptide having a function of crossing a blood-brain barrier. The polypeptide having the function of crossing the blood-brain barrier is RVG29-Cys. The oncolytic virus is a genetically engineered oncolytic virus OH2 in which neurotoxic and immunosuppressive genes in a wild-type virus genome are knocked out and an immune-enhancing human granulocyte-macrophage colony stimulating factor gene is inserted. An OH2-PEG-RVG nanosystem is constructed by conjugating NHS-PEG-Mal to OH2, and then coupling a Mal group on NHS-PEG-Mal to a Cys group on RVG29-Cys, thus increasing the aqueous solubility of a drug while facilitating the therapeutic drug crossing of the blood-brain barrier to treat brain tumors, and preventing neutralizing antibodies and macrophages in vivo from neutralizing and phagocytosing the oncolytic virus, thereby prolonging the circulation time in vivo.

The invention relates to vaccination with immune-isolated cells producing immunomodulators. Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immune-isolated allogeneic cells that secrete an immunomodulator, such as GM-CSF (granulocyte-macrophage colony stimulating factor), and an antigen component (e.g., autologous tumor cells or infectious factors). Also provided herein are kits and pharmaceutical compositions containing the vaccine compositions and said products for use in methods of therapeutic or prophylactic vaccination against tumors or infectious factors.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

The present invention relates to gene therapeutics for the treatment of alveolar proteinosis (PAP), in particular autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors that drive transient and / or low levels of expression of granulocyte-macrophage colony stimulating factor (GM-CSF) that provide therapeutic effects without the presence of toxicity associated with treatment. The invention also relates to related products and animal models of aPAP.

The invention provides a medicine for treating diabetic foot ulcer, and the medicine for treating diabetic foot ulcer provided by the invention is an M2 type macrophage polarization inducer. The M2 type macrophage polarization inducer comprises but is not limited to IL-4, IL-13, IL-10, retinoic acid, a mitogen-activated protein kinase kinase (MEK) inhibitor, a histone deacetylase (HDAC) inhibitor, a granulocyte / macrophage colony stimulating factor and the like, and can be used independently or in a mixed manner. The composition can effectively promote healing of diabetic foot ulcer wounds and pathological improvement of wound inflammation, and the curative effect is obviously better than that of a treatment method in the prior art.

The invention discloses a prokaryotic expression plasmid of a recombinant cat macrophage colony stimulating factor as well as a construction method and application of the prokaryotic expression plasmid, and the construction method of the prokaryotic expression plasmid comprises the following steps: cloning a synthesized cat macrophage colony stimulating factor gene into a PUC57 plasmid to obtain a PUC57-FM-CSF plasmid; and then taking the synthesized PUC57-FM-CSF plasmid as a template, carrying out PCR (Polymerase Chain Reaction) amplification by adopting a homologous recombinant primer designed at the position of a signal peptide sequence removed, purifying a target gene obtained by amplification, subcloning the purified target gene into a corresponding site of a prokaryotic expression vector, and transforming DH5alpha competent cells to obtain the gene. According to the invention, the plasmid containing the cat M-CSF gene is successfully constructed for the first time and is efficiently expressed in a prokaryotic expression system, and the expressed recombinant protein shows higher biological activity after being purified, so that a stable in-vitro research platform is provided for further researching the structure, biological function and the like of the cat M-CSF; the important research significance and clinical application value are realized.

The present disclosure relates to methods of treating severe asthma in a subject using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). Specifically, the present invention relates to gene therapy vectors that drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), resulting in a therapeutic effect without the toxicity associated with the therapy. The present invention further relates to related products and animal models of aPAP.

The invention relates to the technical field of cell biology, in particular to a culture medium for inducing blood-derived cells to be transformed into (muscle) fibroblasts as well as an induction method and application of the culture medium. According to the culture medium provided by the invention, growth factors and bioactive substances with proper concentrations are compounded in a basic culture medium; mononuclear macrophage activating cytokines or substances (macrophage colony stimulating factors or phorbol ester) and macrophage to (muscle) fibroblast transformation inducing factors (transforming growth factors-beta and platelet-derived growth factors-BB) are used, and patient tissue does not need to be cut. Human blood-derived cells (peripheral blood mononuclear cells or mononuclear macrophages) can be converted into (muscle) fibroblasts capable of expressing collagen and smooth muscle protein, and the method can be used for scientific research, regenerative medicine or anti-aging treatment.

The invention discloses a pichia pastoris genetic engineering strain for expressing a recombinant human granulocyte-macrophage colony stimulating factor as well as a construction method and application of the pichia pastoris genetic engineering strain. The pichia pastoris genetic engineering strain GGM4 is classified and named as pichia pastoris (syn.Komagatapha phaffii), and the preservation number of the pichia pastoris genetic engineering strain GGM4 is CGMCC (China General Microbiological Culture Collection Center) No.39117. The engineering strain is obtained by using a pichia pastoris endogenous secretory signal peptide PRY2 and a saccharomyces cerevisiae secretory signal peptide alpha MF in a combined manner and overexpressing pichia pastoris endogenous genes PDI1, SSA4 and SNC2, so that high-efficiency expression of the recombinant human granulocyte-macrophage colony stimulating factor is realized. After the strain is subjected to high-density fermentation in a 3L fermentation tank, the titer of the recombinant human granulocyte-macrophage colony stimulating factor in a fermentation supernatant is greater than 4g / L. The strain can express a high-titer recombinant human granulocyte-macrophage colony stimulating factor, and has wide industrial application value in the field of recombinant protein drug production.

The present disclosure relates to the treatment of neurodegenerative or neurological diseases or disorders with granulocyte-macrophage colony-stimulating factor.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a nasopharynx cancer treatment medicine and application thereof. The tea is prepared from the following raw materials in parts by weight: 8-12 parts of tea leaves, 25-40 parts of pollen typhae, 8-12 parts of bletilla striata, 8-12 parts of radix ophiopogonis, 5-8 parts of mint, 8-12 parts of Chinese wolfberry fruits, 15-30 parts of oldenlandia diffusa, 8-16 parts of wild chrysanthemum flowers, 5-10 parts of paris polyphylla, 8-15 parts of coix seeds, 3-5 parts of selaginella doederleinii hieron, 2-9 parts of radix fici simplicissimae and 42-85 parts of honey compound liquid. The honey complex liquid comprises honey, sucralfate, normal saline, benzydamine, Kangfuxin liquid, a compound borax solution, sodium bicarbonate, chlorhexidine, povidone iodine and granulocyte-macrophage colony stimulating factors. The medicine for treating nasopharynx cancer is dominated by a traditional Chinese medicine compound, has the effects of clearing away heat and toxic materials aiming at the fire-heat toxicity of radioactive rays, and has the effects of strengthening the middle warmer, moistening dryness, relieving pain and detoxifying.

The present invention relates to a method of treating cancer by delivering lipid nanoparticles (LNP) encapsulating an immunostimulant mRNA and a bispecific antibody mRNA into a cancer cell or tumor. The method comprises a step of injection administration of LNP encapsulating mRNA to a tumor focus of a cancer subject. An immunologic stimulant mRNA-LNP can activate immune cells at a tumor site and around the tumor site, and the immune cells, an antibody coded by a bispecific antibody mRNA-LNP and PBMC have a synergistic effect, so that local and distant metastatic tumors are effectively targeted. The preferred immunostimulatory agent is a granulocyte-macrophage colony stimulating factor (GM-CSF), an interleukin-12 (IL-12), and a combination thereof.

The invention relates to the technical field of immunodetection, in particular to a granulocyte-macrophage colony stimulating factor determination kit and a detection method thereof. The granulocyte-macrophage colony stimulating factor determination kit comprises GM-CSF magnetic particles, a GM-CSF luminous marker, an analysis buffer solution, a calibrator 1, a calibrator 2, a quality control product 1 and a quality control product 2, the GM-CSF magnetic particles, a sample or a calibration product or a quality control product and an analysis buffer solution are sequentially added, incubation cleaning is performed, then a GM-CSF luminous marker is added, incubation cleaning is performed, then a substrate A solution and a substrate B solution are sequentially added, the luminous intensity is immediately measured, the GM-CSF concentration is calculated according to a calibration curve, the total detection time can be controlled to be about 1 hour, the detection efficiency is greatly improved, and the detection cost is reduced. The detection method is simple and convenient to operate, the result is rapid and accurate, and automatic high-throughput detection is easy to realize.